JP2008545616A5 - - Google Patents

Download PDF

Info

Publication number
JP2008545616A5
JP2008545616A5 JP2007555704A JP2007555704A JP2008545616A5 JP 2008545616 A5 JP2008545616 A5 JP 2008545616A5 JP 2007555704 A JP2007555704 A JP 2007555704A JP 2007555704 A JP2007555704 A JP 2007555704A JP 2008545616 A5 JP2008545616 A5 JP 2008545616A5
Authority
JP
Japan
Prior art keywords
dopa
dopamine agonist
medicament
treatment
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007555704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008545616A (ja
Filing date
Publication date
Priority claimed from GB0503540A external-priority patent/GB0503540D0/en
Priority claimed from GB0508843A external-priority patent/GB0508843D0/en
Application filed filed Critical
Priority claimed from PCT/GB2006/000583 external-priority patent/WO2006087577A2/en
Publication of JP2008545616A publication Critical patent/JP2008545616A/ja
Publication of JP2008545616A5 publication Critical patent/JP2008545616A5/ja
Withdrawn legal-status Critical Current

Links

JP2007555704A 2005-02-21 2006-02-20 ジスキネジーの阻害または治療 Withdrawn JP2008545616A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0503540A GB0503540D0 (en) 2005-02-21 2005-02-21 Inhibition or treatment of dyskinesia
GB0508843A GB0508843D0 (en) 2005-04-29 2005-04-29 Inhibition or treatment of dyskinesia
PCT/GB2006/000583 WO2006087577A2 (en) 2005-02-21 2006-02-20 Inhibition or treatment of dyskinesia

Publications (2)

Publication Number Publication Date
JP2008545616A JP2008545616A (ja) 2008-12-18
JP2008545616A5 true JP2008545616A5 (enExample) 2009-04-09

Family

ID=36691702

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007555704A Withdrawn JP2008545616A (ja) 2005-02-21 2006-02-20 ジスキネジーの阻害または治療

Country Status (6)

Country Link
US (1) US20080070952A1 (enExample)
EP (1) EP1850838A2 (enExample)
JP (1) JP2008545616A (enExample)
CA (1) CA2598484A1 (enExample)
SG (1) SG160342A1 (enExample)
WO (1) WO2006087577A2 (enExample)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0891332B1 (en) * 1996-03-29 2004-03-17 Pfizer Inc. 6-phenylpyridyl-2-amine derivatives
HN1997000027A (es) * 1996-12-06 1997-06-05 Pfizer Prod Inc Derivados de 6-fenil piridil - 2 amina
KR100460399B1 (ko) * 1997-02-10 2004-12-08 화이자 프로덕츠 인코포레이티드 2-아미노-6-(2-치환된-4-페녹시)-치환된-피리딘
WO1998048826A1 (en) * 1997-04-30 1998-11-05 Northwestern University Inhibition of nitric oxide synthase by amino acids and dipeptides
WO2003000198A2 (en) * 2001-06-22 2003-01-03 Northwestern University Selective neuronal nitric oxide synthase inhibitors
US20030232739A1 (en) * 2001-08-15 2003-12-18 Pfizer Inc. Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist
DOP2002000467A (es) * 2001-10-10 2003-04-15 Pfizer Prod Inc 2-amino-6 (fenilo sustituido en las posiciones 2,4,5)-piridinas
US6803470B2 (en) * 2001-10-10 2004-10-12 Pfizer Inc 2-amino-6-(2,4,5-substituted-phenyl)-pyridines
EP1670478A4 (en) * 2003-09-08 2009-05-06 Univ Northwestern HETEROAROMATIC SELECTIVE INHIBITORS OF NEURONAL STITCHOXIDE SYNTHASE

Similar Documents

Publication Publication Date Title
EP2444072A3 (en) Non-mucoadhesive film dosage forms
CA2683786C (en) Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects
JP2013505282A5 (enExample)
FI3782612T3 (fi) Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
WO2008064192A3 (en) Modified release analgesic suspensions
WO2008011426A3 (en) Methods and medicaments for administration of ibuprofen
WO2008157103A3 (en) Modified release solid or semi-solid dosage forms
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
UA105644C2 (uk) Способи лікування легеневих порушень складами ліпосомального амікацину
JP2013541583A5 (enExample)
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
CL2007002574A1 (es) Composicion farmaceutica oral que comprende levodopa en una dosis unitaria de alrededor de 100 hasta alrededor de 500 mg y un excipiente adecuado; y su uso para tratar parkinson.
JP2013536837A5 (enExample)
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
MX338975B (es) Composicion farmaceutica que contiene sales de citrato y bicarbonato, y su uso para el tratamiento de la cistinuria.
WO2007145863A3 (en) Sustained release formulation of naltrexone
TNSN08506A1 (en) Substituted carboxamides
JP2011500589A5 (enExample)
RU2008134143A (ru) Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения
NZ591328A (en) Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof
UA90893C2 (ru) Пероральная дозированная форма производных гемцитабина
JP2008545616A5 (enExample)